More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

The biopharma industry, both biopharmaceutical/pharmaceutical companies and CDMOs/CMOS, has been a target of increased investment by private-equity (PE) firms. A recent analysis by Bain & Company examines financing trends and investments by PE...

Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent expansions for drug substances and drug...

Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), immunotherapies by Roche and AstraZeneca are joining the...

As lockdown measures to COVID-19 are slowly being lifted globally, how are companies responding? A recent PwC survey of nearly 870 CFOs in 24 territories examines companies' plans with respect to supply chains, sourcing, capital expenditures,...

Following AbbVie's $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights examines the key products, both...

Operation Warp Speed, a US government initiative to accelerate development of 14 promising vaccine candidates against COVID-19, was launched last week (May 15, 2020). What is behind the initiative, and how does it fit with other international...